At Ardelyx, we are dedicated to improving the lives of patients by developing and commercializing first-in-class targeted therapies that advance patient care. Using our discovery model, Ardelyx scientists have identified completely new biological mechanisms and pathways that have enabled us to develop a pipeline of drug candidates designed to better manage complications related to kidney and cardiovascular diseases, to improve outcomes for this large population of underserved patients.